Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 30.09.2021 | 16:20

Leadership Change in the Executive Board of Carl Zeiss Meditec AG

Carl Zeiss Meditec AG / Key word(s): Personnel
Leadership Change in the Executive Board of Carl Zeiss Meditec AG

30-Sep-2021 / 16:20 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Leadership Change in the Executive Board of Carl Zeiss Meditec AG

Jena, September 30, 2021

The Supervisory Board of Carl Zeiss Meditec AG (ISIN: DE0005313704) has agreed on a change in the Executive Board of the company. Dr. Ludwin Monz, who has been Chief Executive Officer of the company since 2010, will turn over his position to Dr. Markus Weber, currently member of the Executive Board of Carl Zeiss AG, on December 31, 2021. The transition is happening on the best of terms and at Dr. Monz' own request.

Dr. Weber has more than 20 years of experience in various management and research and development functions within the ZEISS Group and, on the Executive Board of Carl Zeiss AG, is currently responsible for the Semiconductor Technology segment. Along with his new role as Chief Executive Officer of Carl Zeiss Meditec AG, Dr. Weber will remain on the board of Carl Zeiss AG, assuming the responsibilities of Dr. Monz on that board, who will leave the Executive Board of Carl Zeiss AG on December 31, 2021.

In the view of the Supervisory Board of Carl Zeiss Meditec AG, management continuity is assured via the internal succession. The other two members of the Executive Board, Justus Felix Wehmer and Jan Willem de Cler, will remain in their current positions.

Contact for investors and press
Sebastian Frericks
Head of Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116

30-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.

29. November 2021